You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬泰生物(603392.SH)業績快報:2020年淨利升224.13%至6.77億元
格隆匯 03-04 18:46

格隆匯3月4日丨萬泰生物(603392.SH)披露2020年度業績快報,報吿期內,公司實現營業收入23.54億元,同比增長98.88%%;營業利潤7.75億元,同比增長255.06%;利潤總額7.64億元,同比增長252.59%;歸屬於上市公司股東的淨利潤6.77億元,同比增長224.13%;基本每股收益1.62元,同比增長200%。

公司2020年營業收入及利潤大幅增加的主要因素:1、公司新產品二價宮頸癌疫苗(HPV2)於2020年5月正式上市銷售,銷售情況良好,使得疫苗業務的銷售收入及利潤實現了大幅增長;2、為應對2020年突發的新冠疫情,公司及時推出新冠檢測試劑及原料,新冠試劑和原料的收入及利潤大幅增加;3、開展了與GSK、巴斯德國外公司的技術合作,實現了對收入及利潤的貢獻。

報吿期末,公司總資產35.04億元,比期初增長61.84%;歸屬於上市公司股東的所有者權益25.54億元,比期初增長63.82%;2020年末股本4.336億元,比期初增長11.18%;2020年末歸屬上市公司股東的每股淨資產5.89元,比上年同期增長47.25%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account